Executive Vice President & Director, CTO, Rohto Pharmaceutical Co.,Ltd.
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) dividends retained by asset-management companies (less about 20% corporate tax), and proceeds from share sales (the drop in shares from the previous year × share price, less 20.315% tax, or about 30% for asset-management companies), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| Rohto Pharmaceutical Co.,Ltd. 4527 · FY ending Mar 2026 · Executive Vice President & Director, CTO |
Own name | 45,000 | — | ¥2,410 | ¥108M | ¥2.1M |
| Year | Net worth | Pay | Dividends | Total income | Taxes (est.) | After tax (est.) | Share sales (after tax) |
|---|---|---|---|---|---|---|---|
| 2026 | ¥108M | ¥53.9M | ¥2.1M | ¥56.0M | ¥23.5M | ¥30.5M | — |
| 2025 | ¥96.0M | ¥55.1M | ¥1.5M | ¥56.7M | ¥24.0M | ¥30.6M | — |
| 2024 | ¥122M | ¥49.4M | ¥1.1M | ¥50.6M | ¥20.8M | ¥27.8M | — |
| 2023 | ¥108M | ¥63.0M | ¥1.2M | ¥64.2M | ¥28.4M | ¥33.9M | — |
Grouped by the calendar year of each company's fiscal year-end. Years in which the person was not among the top 10 shareholders of a company exclude that company.
Estate ¥231M = listed shares in own name ¥108M + other assets (est.) ¥123M
Total inheritance tax paid: ¥17.4M (7.5% of the estate).
| Heir | Inherits | Tax | After tax |
|---|---|---|---|
| Spouse | ¥116M | ¥0 | ¥116M |
| Each child | ¥57.8M | ¥8.7M | ¥49.1M |
Japanese inheritance tax, assuming the estate is split in statutory shares. A spouse pays no tax up to ¥160M or the statutory share, whichever is larger. Family size is not in the securities reports, so you can choose it (with no children, parents or siblings also become heirs, so the real figure differs). Business-succession deferrals, lifetime gifts, donations to foundations, debts and other reliefs are not reflected.